Bicycle Therapeutics plc (NASDAQ:BCYC) Receives $29.14 Average Target Price from Analysts
Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among […]
Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among […]
